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INTRODUCTION
Numerous laboratories utilising a diverse range of techniques are quantifying the absolute abundance of proteins by quantitative targeted absolute proteomic (QTAP) strategies in mammalian tissues and in vitro cell systems. Up to ten-fold differences in absolute abundances have been observed for specific drug transporter isoforms in independent samples between laboratories, for example, hepatic organic anion transporting polypeptide (OATP) OATP1B1 (Prasad et al., 2014; Vildhede et al., 2014) . Differences in the proteomic workflow including techniques required to: (i) select and generate the peptide standard(s); (ii) generate an enriched membrane fraction; (iii) denature and digest the proteins; (iv) separate the peptides by chromatography and (v) conduct mass analysis of the selected peptides and peptide fragments (LC-MS/MS) may underlie this variability.
Studies have investigated the impact of methodological differences on quantification of transporter protein abundances. For example, the type of solubilizing agent used prior to protein digestion has been shown to influence the quantification of OATP proteins in HEK293 transfected cells (Balogh et al., 2013) and can be a significant source of variability between studies. The selection of the peptide standard is also likely to be important and its influence on protein abundance quantification requires verification. In a recent study, the choice of peptide standard was considered to bias end-point abundance quantification of hepatic OATP1B1 (Terasaki et al., 2014) . However, in a comparable study by Prasad et al., there was also an impact of peptide choice on OATP1B1 abundance using two of the same peptides as Terasaki et al., 2014 , yet little influence of peptide choice for P-glycoprotein (Pgp), Breast Cancer Resistance Protein (BCRP), OATP1B3 and OATP2B1 was observed (Prasad et al., 2014) . The digestion strategy employed might also influence the capacity to This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 2, 2015 as DOI: 10.1124/dmd.115.067371 at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from DMD #67371 5 quantify protein abundances and to generate peptides that suffer missed-cleavage by trypsin (Chiva et al, 2014) . Studies comparing different proteomic approaches within a laboratory found that when comparing immunoblotting to stable isotope labelling of amino acids in culture/mammals (SILAC/SILAM) techniques, there was a reasonable agreement within the same samples to the absolute quantification (AQUA) method routinely employed (Kamiie et al., 2008; Qiu et al., 2013; Prasad and Unadkat, 2014a) .
After showing a direct relationship between activity and abundance, the absolute transporter protein abundance and the inter-individual variability are required in order to generate representative populations within Physiologically-Based Pharmacokinetic (PBPK) models.
Furthermore, a relative expression factor (REF) , the ratio of the transporters' in vivo expression to that in the in vitro system, enables the impact of transporter activity on oral drug absorption to be assessed using an IVIVE-PBPK strategy (Harwood et al., 2013) .
Establishing if differences in abundances reported across laboratories are derived from interindividual variability of a sample set or population, variability associated with assay-specific techniques and/or specific data analysis methods within each laboratory are crucial for generating robust system parameters that can be employed in PBPK models that represent in vivo abundances. Considering the dramatic increase in the use of IVIVE-PBPK models for decision making in pharmaceutical company drug development pipelines, as well regulatory submissions over the last 5 years (Huang et al., 2013; Shepard et al., 2015) , better insight into the comparability of various quantification of transporter protein absolute abundances is becoming essential.
To address if there are laboratory-specific differences in generating system parameters for undertaking transporter-mediated IVIVE-PBPK, a multi-center study evaluating the consistency and comparability of the preparation steps and analytic outcome has been advocated (Harwood et al., 2014) . However, to our knowledge, studies comparing the This article has not been copyedited and formatted. The final version may differ from this version. While not within the scope of this article, the impact of those laboratory-specific REF values on predicted pharmacokinetic outcomes in an IVIVE-PBPK model are provided in an accompanying study (Harwood et al., 2015, submitted) . The aim of this study was to compare the absolute transporter abundances for 3 transporter proteins; Na/K-ATPase, P-gp and BCRP in matched Caco-2 cell and human intestinal total membrane fractions, quantified by two independent laboratories, the University of Manchester (UoM), Manchester, UK, and Bertin Pharma (BPh), Orleans, France, in which each laboratory utilised different QTAP workflows.
These data were used to generate REFs for intestinal Na/K-ATPase (REF iNa 
MATERIALS and METHODS
Human Intestinal Tissue
Human intestinal tissue (n = 3 distal jejunum and n = 1 distal ileum) was obtained after informed consent from patients undergoing elective intestinal surgery at Salford Royal NHS Foundation Trust, Salford, UK. Prior ethics committee approval had been granted by the North West Research Ethics Committee, UK, (12/NW/0306) and all procedures were carried out in accordance with the Declaration of Helsinki guidelines. Patients suffering from inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis) and/or known to be affected by hepatitis B were excluded from participation. Donor demographics and drug history have are provided in the Supplemental Information (Table S1 ).
Cell Culture
Caco-2 cells were purchased from the American Type Tissue Culture Collection (ATCC, Rockville, MD, USA) at passage 18. Additionally, cryopreserved higher passage Caco-2 cells were used, that were originally obtained from the ATCC and were subsequently cultured to a passage greater than 100 in the laboratories of the Biomedical Facility, Salford Royal 
Human Enterocyte and Caco-2 Total Membrane Fractionation
Total membrane preparations were isolated by differential centrifugation after eluting human enterocytes by a calcium chelation protocol . Caco-2 cell monolayers total membrane preparations were obtained after overnight lysing by differential centrifugation (Russell et al., 2013) . Protein content was determined by the BCA assay.
Shipping/Transfer of Total Membrane Fractions
Total membrane samples were treated differently based on the specific protocols employed within each laboratory.
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Proteolytic Digestion
At BPh, total membrane proteins (50 μ g) were digested by the MS2 Plex assay kit developed by BPh and based on techniques developed at Tohoku University, Sendai, Japan including reduction, alkylation and an overnight tryptic digestion step (Kamiie et al., 2008 , Kunze et al., 2014 . The digestion strategy at the UoM was an adapted in-solution digest of 50 μ g of total membrane protein based on established methods (Balogh et al., 2013) and also accounts for peptide losses by a gravimetric method . The digestion and analysis of the samples took place within a 1 month period between laboratories, a time period considered unlikely to impact on end point abundance determinations (Sakamoto et al., 2011) .
Determination of Transporter Abundances
Different QTAP workflows were employed within each laboratory; BPh employ an AQUA approach whereas the UoM utilise a Quantification CONcatamer (QconCAT) approach. The key differences between the AQUA and QconCAT approaches employed by BPh and UoM, respectively, are that (i) AQUA standard peptides are generated by chemical synthesis μ g) entering the digestion phase of the workflow, and for the UoM it is the peptide content entering the sample tube for injection onto the chromatography column after correction for losses by a gravimetric method .
The choice of peptides within the entire protein sequence for Na/K-ATPase, P-gp and BCRP is provided in Figures S1, S2 and S3 in the Supplemental Information.
Statistical Analysis
The abundance data were tested for normality using the Kolmogorov-Smirnov normality test. maintained by keeping the proteomic analysts at both BPh and UoM blinded as to the results of the abundance quantifications on the matched samples.
Relative Expression Factor (REF) Generation
Based on abundance data in the distal jejunum samples (n=3) and 21d filter-grown Caco-2 monolayers (n=3 experiments on different days, based on n=3 pooled filter per experiment), a REF for IVIVE was generated (using Equation 1) for all 3 proteins. The REFs were based on 21d, rather than 29d-grown Caco-2 monolayers, as a monolayer of this age is more commonly used for drug transport assays in the industry.
Although absolute expression values were generated in this study, they were set relative to each other (Equation 1), thus one REF was obtained for each of the proteins (Na/K-ATPase, P-gp and BCRP) for each laboratory.
RESULTS
Inter-Laboratory Method Differences between Groups Quantifying Transporter
Protein Absolute Abundances
To give perspective to this cross-laboratory study, a literature analysis of the diversity of techniques used by different laboratories for transporter absolute abundance quantification was undertaken. Fifteen laboratories have reported quantification of transporter abundances in mammalian tissues or in in vitro systems. Table 2 highlights the general differences in methods for sample preparation, peptide selection, digestion strategies and analytical systems and shows that there is considerable variation in the methodologies used to quantify transporter abundances. The predominant approach has been to use synthetically made isotope labelled standard peptides like AQUA. However, a combination of label free and targeted (labelled) approaches have also been utilized simultaneously within the same study (Karlgren et al., 2012) . BPh provides QTAP services and kits based on technologies developed at Tohoku University and, as a result, the workflows from both laboratories share many similarities. In fact, several laboratories foster links with the forerunning developers of these methodologies, i.e., Tohoku University and Pfizer Ltd., (Groton, CT, USA). Peptides that are used as surrogates for the quantification of the complete protein are selected based on a variety of criteria (Ohtsuki et al., 2011; Oswald et al., 2013; Prasad and Unadkat, 2014b; Qiu et al., 2014) . Consequently, for the frequently quantified transporter protein P-gp, three peptides are routinely employed to quantify human P-gp (AGAVAEEVLAAIR/ NTTGALTTR/ FYDPLAGK; and Barber, 2013). Nano and normal flow LC approaches are used but the advantages of one approach over another have not been discussed within these studies. The triple quadrupole MS system is routinely employed for targeted approaches, however the manufacturers and models differ between laboratories. For comparative purposes, the use of quantitative immunoblotting is also incorporated in this analysis. This approach does not employ peptide selection strategies, protein digestion and LC-MS/MS for analysis, but relies on selective antibodies being available for target transporters, which is not always the case (Tucker et al., 2012) .
Cross Laboratory Comparison of Transporter Absolute Protein Abundances
Quality Control: The analytical quality control for Na/K-ATPase, P-gp and BCRP was The analytical quality control for the same proteins established at the UoM has been reported in detail by Harwood and co-workers . The linearity for abundance determination of each peptide in the presence of a biological matrix (i.e., human intestinal total membrane protein) was established. In addition, linearity in the quantification of the QconCAT used by UoM was determined using the internal calibrator NNOP peptide GluFibrinopeptide B (glu-fib) . The intra-day and inter-day precision and relative error across biological samples was also measured as part of the quality control procedure. The LLOQ for abundance determinations at UoM was 0.2 fmol/μg for all proteins.
This article has not been copyedited and formatted. The final version may differ from this version. The BCRP peptides selected by both groups showed no evidence of SNP's. The peptide selection criteria applied by Tohoku University are unlikely to have scored the UoM peptide highly due to the presence of glutamine (Q) which has the potential to suffer a deamidation post-translational modification. This event was judged tolerable at UoM, given that the rate of glutamine deamidation is considerably lower than that for asparagine (N), with a reaction half-life of 660 days (Li et al., 2010b) . The selection criteria employed by UoM would have rejected the BPh BCRP peptide standard due to the anticipated difficulty of efficient trypsin cleavage at dibasic and tribasic tryptic sites, i.e., sequential lysine or arginine residues or lysine and arginine side-by-side at the N-terminal region of the BPh peptide (Lawless and Hubbard, 2012).
Transporter Abundances in Caco-2 and Human Intestinal Samples: Total membrane
fractions from seven Caco-2 cell monolayers, three human distal jejunum and a single human distal ileum were analysed in each laboratory (n = 11). The comparative absolute abundances and the correlations between BPh and UoM for Na/K-ATPase, P-gp and BCRP are provided in Figures 2 and 3 , respectively. The individual abundance data for each sample is provided in Table 3 . For Na/K-ATPase and BCRP, there was no difference in the mean abundances (p = 0.36 and 0.76, respectively, Wilcoxon matched pair test) with a moderate correlation for Na/K-ATPase (Rs = 0.42) and no correlation for BCRP (Rs = 0.39) using a Spearman Rank correlation analysis across all samples between laboratories. A systematically higher BCRP abundance was quantified by BPh compared to UoM in 21 and 29d cultivated Caco-2 cells ranging from 20 to 129% in individual samples (Table 3) . This was not reciprocated in the intestinal BCRP abundances, which were on average 17% higher (range; -40 to 72%) in the UoM analysis. A systematically and significantly higher (63%, p = 0.001, Wilcoxon matched pair test) P-gp abundance was quantified by UoM compared to BPh across all samples and, in contrast to Na/K-ATPase and BCRP, P-gp abundances were highly correlated (Rs = 0.72, p = This article has not been copyedited and formatted. The final version may differ from this version. Figure 3B ). For the single distal ileum sample, P-gp abundance was below the LLOQ (< 0.125 fmol/μg) in BPh determinations, but the UoM determined a value of 0.2 fmol/µg total membrane protein. In both laboratories, lower mean abundances of P-gp were observed in the human intestinal samples than Caco-2 cell monolayers, irrespective of cultivation time. This is in contrast to BCRP, in which the opposite relationship was observed. The importance of correcting for losses of peptides during reduction, alkylation and digestion steps when determining absolute transporter abundances has been established .
These corrections were applied only to abundance determinations at the UoM, since they are not a routine component of abundance determinations at BPh. When peptide loss corrections
were not applied to samples quantified at the UoM, P-gp abundances were still systematically and significantly higher (52%, p = 0.001, Wilcoxon matched pair test), and Na/K-ATPase and BCRP abundances were also still not significantly different (p = 0.36 and p = 0.58, respectively, Wilcoxon matched pair test).
Generation of Relative Expression Factors (REF):
The potential impact of these results on IVIVE scaling was investigated by generating a REF (Equation 1) for human distal jejunum samples and 21d cultivated Caco-2 cell monolayers (n = 3, Table 3 ). Due to the high correlation observed between laboratories when quantifying P-gp abundances, the systematically higher P-gp levels measured by the UoM had no effect on the REF between 
DISCUSSION
Several laboratories have developed and validated protocols for quantifying transporter protein abundances in biological systems using proteomic approaches (Table 2) . With this raft of abundance data generated across multiple laboratories now being incorporated into IVIVE-PBPK strategies (Bosgra et al., 2014; Kunze et al., 2014; Prasad et al., 2014; Vildhede et al., 2014) , it is critical to establish if laboratory-specific methodologies contribute to a bias in abundance determination. To address this, membrane protein samples from human intestine and Caco-2 monolayers were analysed independently by two laboratories, BPh and UoM. For P-gp, there is a systematic bias in abundances between laboratories. For Na/KATPase and BCRP, mean abundances reported by BPh and UoM were similar across all samples; however the limited correlation in abundances of these transporters in individual samples suggests a potential influence of technical and/or analytical variability in postmembrane processing between laboratories.
Efficient protein digestion is critical for abundance determination and integral membrane transporter proteins are notoriously challenging to digest due to their poor solubility (Mirza et al., 2007) . Therefore, different solubilizing agents are often used to enhance protein solubility facilitating target protein digestion. Based on the findings of Balogh et al. (2013) , UoM employed sodium deoxycholate as the solubilizing agent. However, BPh, do not disclose the components of their MS2Plex digestion kit, and therefore, a systematic evaluation of the effect of potential differences in the procedures employed in both laboratories to denature, reduce, alkylate and digest the proteins cannot be undertaken.
Critical to the quantification of transporter protein abundances is that enzymatic digestion is complete (Ji et al., 2012) . The digestion efficiency for selected peptides has been assessed in several studies (Kamiie et al., 2008; Li et al., 2008; Zhang et al., 2011; Ji et al., 2012; This article has not been copyedited and formatted. The final version may differ from this version. Gröer et al., 2013; van de Steeg et al., 2013) . However, assessing digestion completeness is a significant challenge due to the limited availability of purified transporter proteins used to monitor peptide digestion (Prasad et al., 2014; . Peptide instability over the duration of digestion should be considered and could be a factor in MS signal reduction (van den Broek et al., 2013) . The digestion strategy at UoM incorporated a lysyl-endoproteinase as a priming step prior to trypsin incubation, cleaving the C-terminal side of lysine residues, generating lysine terminated peptides to improve trypsin digestion efficiency (Achour and Barber, 2013) . Within this study, it is assumed, based on prior optimization, that digestion achieves a steady-state over the time course of incubation with the proteolytic enzymes within the biological matrices under investigation for both laboratories; therefore, any source of variability between samples should not result from inefficient digestion.
Selecting peptides that uniquely identify the targeted protein based on trypsin digestion are required. The peptide (AAVPDAVGK) selected by BPh to quantify Na/K-ATPase (ATP1A1)
is not unique as the sequence is also found in human Na/K-ATPase α 2 subunit (ATP1A2) (Shull and Lingrel., 1987) . Peptides possessing a lower potential for missed cleavage events are also advantageous (Lawless and Hubbard, 2012) . This is pertinent given that in relative quantification analysis, up to 46% of peptides generated mis-cleaved events after in-solution trypsin digestion in E. coli (Chiva et al., 2014) . For the peptide (AAVPDAVGK) selected for Na/K-ATPase quantification by BPh, the C-terminal lysine is closely followed by an arginine quadrupole mass spectrometer is based on pre-defined masses, where any violation of these masses, i.e., by missed cleavage of target peptide, leads to the peptides exclusion in mass filter 1 (Q1), resulting in lower abundance measurements. These events may explain the differences in P-gp abundance quantification between laboratories shown in this study.
Interestingly, Miliotis and co-workers (2011) used the same peptide selected by UoM (AGAVAEEVLAAIR) to assess the abundance of P-gp in 29d-grown Caco-2 monolayers, reporting an abundance of 7.89 fmol/μg total membrane protein, similar to UoM (6.92 fmol/μg total membrane protein) and much higher than quantification by BPh (1.97 fmol/μg total membrane protein). This lends support to the conjecture that peptide selection may contribute to bias in abundance measurements. UoM and BPh in this study is smaller (63% , Table 3) , however, this level of methodological bias in abundance determination is of concern when incorporating population abundances into PBPK models, given the potential effect on predicted transporter-mediated drug disposition (Harwood et al., 2013) .
This article has not been copyedited and formatted. The final version may differ from this version. The consistently lower BCRP abundance in Caco-2 cells reported by UoM in this study (Table 3 , Figures 2C and 3C ) does not appear to be peptide-specific since BCRP abundances in 3 out of 4 human samples were higher at UoM than BPh. One possible explanation is that the Caco-2 cell membrane matrix may affect digestion of the selected BCRP peptide ( Figure   1 ) impacting on abundance quantification. Chromatographic effects may also contribute to these differences, as reported for NTTGALTTR, a peptide commonly used to quantify P-gp (Gröer et al., 2013) . Chromatographic interference is unlikely to be the source of the observed lower BCRP abundances in Caco-2 cells as co-elution profiles (i.e., identical retention times) of native and standard peptides were generated. However, the methodological validation of these peptides was initially performed in human intestine . Further studies assessing the optimal digestion conditions for the selected BCRP peptides in Caco-2 cells are warranted. Additionally, this study does not control for different membrane fractionation techniques, which was recently suggested as a source of variability between and within studies (Heikkinen et al., 2015) . To test this, repeated membrane extraction, protein digestion and subsequent abundance quantification is required on the same tissue over multiple days. This would remove variability associated with technical/analytical procedures from the intrinsic biological variability, a requirement for building representative IVIVE-PBPK frameworks with population variability.
In addition to obtaining transporter abundances in tissues of individuals for incorporation into PBPK models, abundance data from mammalian tissues and in vitro systems is used to generate IVIVE scaling factors (Li et al., 2010a; Karlgren et al., 2012; Vildhede et al., 2014) .
This study generated laboratory-specific REF-IVIVE scaling factors for all three transporters using abundance data for jejunum and Caco-2 monolayers. This enabled the assessment of laboratory-specific biases in abundance measurements on REF. systems. However, if bias in abundance quantification occurs selectively within a biological system between laboratories (i.e., Caco-2 cell BCRP abundances being nearly 2-fold higher at UoM), the laboratory-specific REF is affected and can be significantly different.
The results of this study for the first time show significant differences in transporter protein abundance reported on the same samples by different laboratories, implying methodological bias is likely to be a significant source of variability. Thus, caution should be exercised when utilising absolute mammalian tissue abundances from literature sources to estimate whole organ abundances and REFs in IVIVE-PBPK strategies. Across-laboratory protein abundance comparisons on the same samples can reveal biases that are integral to a particular laboratory, or a laboratory-specific step within a workflow. We recommend further comparison studies using matching samples across a wider range of laboratories, including the complete workflow-specific to each laboratory to establish the critical factors influencing protein abundance quantification. Subsequently, by selecting the technique/operating procedure with the most favorable precision, accuracy and reproducibility, a further study using the same biological samples as the first comparative analysis can commence. The overall aim is to reduce method-dependent variability to an aceptable minimum, so the intrinsic biological variability can be determined with high accuracy in any laboratory using the same workflow.
Finally, to what extent do variations in REF caused by differences in transporter abundance
data between laboratories influence the prediction of oral drug absorption by IVIVE-PBPK models? Assessing the impact of REFs from different sources on PK parameters by IVIVE-PBPK strategies is addressed in the accompanying study (Harwood et al., 2015 submitted) .
